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 Mutations in the paired-box 6 (PAX6) gene cause aniri-
dia in man, a panocular disorder primarily characterized by
complete or partial absence of iris tissue. Aniridia is often as-
sociated with other ocular abnormalities including corneal dys-
trophy, cataract, and glaucoma. The disease has a high pen-
etrance, but variable expressivity, and, within pedigrees, phe-
notypes can vary in patients having the same mutation [1].
The incidence of aniridia is 1:65,000-1:100,000 in man, and
approximately 2/3 of aniridia cases are inherited. In addition
to aniridia, PAX6 mutations (OMIM 607108) can also cause
Peter’s anomaly, cataract, corneal dystrophy, keratitis,
coloboma, ectopic pupillae, foveal hypoplasia, and optic nerve
hypoplasia. Over 300 PAX6 mutations have been described in
man, and can be viewed at the Human PAX6 Allelic Variant
Database. PAX6 mutations are dominant to semidominant and
homozygous lethal. Homozygous or compound heterozygous
patients have anophthalmia and multiple, severe CNS malfor-
mations [2,3].
PAX6 is expressed during embryogenesis in the develop-
ing CNS, eye, nose, pituitary, and pancreas [4-8]. It functions
as a master control gene in ocular development across spe-
cies, both vertebrate and invertebrate, and is able to induce
ectopic eye development in Drosophila melanogaster [9] and
Xenopus laevis [10]. Mutations in the Drosophila PAX6 ho-
molog eyeless cause partial to complete loss of the compound
eye, and surrounding sensory bristles [11]. Pax6 mutations in
mouse are dominant, and result in the small eye (sey) pheno-
type characterized by microphthalmia and small body size [12].
Experimentally induced mutations in mouse Pax6 exhibit a
range of phenotypes, including partial to complete aniridia,
iris abnormalities, cataract, and corneal adhesions [13]. Ho-
mozygous Pax6 mutations are lethal in the mouse, and, as in
man, result in small embryos with anopthalmia and severe
CNS malformations [3,12].
PAX6 is a highly conserved member of the PAX family of
DNA-binding transcription factors. It contains a paired do-
main (PD), a linker region, a homeodomain (HD), and a pro-
line-serine-threonine rich (PST) region which functions as a
transcription activator [3]. Both the paired and homeo domains
of the PAX6 protein recognize and bind to DNA target se-
quences. The paired domain is further divided into an NH2-
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causal associations with inherited aniridia in dogs.
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431terminal subdomain (NTS) and a COOH-terminal subdomain
(CTS). An alternatively spliced form of PAX6 inserts an addi-
tional 14 amino acids, encoded by exon 5a, into the NTS of
the paired domain, thereby altering its binding ability [14,15].
In the shorter PAX6, the NTS binds to DNA targets while in
the longer PAX6(5a) the CTS preferentially binds. Thus, the
NTS and the CTS apparently negatively regulate each other
allowing the alternatively spliced exon 5a to act as a molecu-
lar switch which can determine DNA-binding targets [14,16].
In an effort to identify the causal gene, and mutation re-
sponsible for canine aniridia, a family of Spanish Catalan
sheepdogs with an inherited form of aniridia was analyzed.
Affected dogs presented with partial to nearly complete ab-
sence of the iris with or without keratitis, cataract, and glau-
coma. Because limited pedigree information and samples pre-
cluded a genome wide scan, a candidate gene approach was
used. PAX6 was selected for evaluation because it is the pri-
mary aniridia gene in man. The canine PAX6 has not been
cloned, and the current draft of the canine genomic sequence
[17] does not contain an annotated PAX6. Moreover, the ca-
nine draft genomic sequence does not contain the entire se-
quence for this gene. As a result, PAX6 was cloned from a
canine retinal cDNA library, characterized, and evaluated for
mutations that could be causally associated with the disease.
METHODS
Animals and DNA:  Catalan sheepdogs (Gos d’Atura) with an
inherited form of aniridia were ascertained by Dr. Manuel
Villagrasa at the Veterinary Ophthalmology Center in Madrid,
Spain [18]. The dogs were privately owned pets or working
sheepedogs, and were not part of a research colony. Dogs were
examined using direct and indirect ophthalmoscopy and slit
lamp biomicroscopy. Clinical signs included partial to nearly
complete absence of the iris with ciliary processes visible at
the circumferential border (Figure 1). Some canine patients
also exhibited persistent remnants from the pupillary mem-
brane, corneal edema, keratitis, cataract, and glaucoma. A to-
tal of 10 dogs were examined, including 7 which were part of
one pedigree (GD2, GD3, GD5, GD6, GD8, GD9, and GD10;
Figure 2), and 3 which were unrelated (GD12, GD13, and
GD14). Six dogs were affected with aniridia (GD5, GD6, GD9,
GD10, GD12, and GD14), and 4 were normal (GD2, GD3,
GD8, and GD13). Although the pedigree information avail-
able was very limited, the disease appeared to segregate as an
autosomal recessive trait in that aniridia-affected dogs were
produced from phenotypically normal parents (Figure 2) [18].
Whole blood was collected in EDTA-anticoagulant tubes, and
total genomic DNA (gDNA) was extracted from blood lym-
phocytes using standard phenol:chloroform extraction proto-
cols with ethanol precipitation [19].
Cloning and characterization of canine PAX6: Oligo-
nucleotide primers were designed based on human
(XM_012065) and mouse (X63963) PAX6 consensus se-
quences using Amplify© software (Bill Engels, University of
Wisconsin, Madison, WI). PAX6 was amplified from a canine
retinal cDNA library made with the pBK-CMV phagemid
vector (Stratagene, LaJolla, CA), using primers listed in Table
1. Vector primers PBKIII and PBKVI from the cDNA library
were used to extend the resulting PAX6 sequence in the 5' and
3' directions, respectively. Additional sequence information
was obtained from The Institute for Genomic Research (TIGR)
1.5X (poodle) canine genomic sequence [20]. Additional prim-
ers were designed to cross introns in gDNA in order to obtain
the intron/exon boundary sequences which were then used to
design primers for exon scanning. Intron/exon boundaries were
analyzed, and intronic sizes were determined for 9 of the 13
introns. For the larger introns (2, 4, 7, and 11), which could
not be amplified directly, genomic sequence at the intron/exon
boundaries was obtained from TIGR (poodle) canine genomic
sequence [20], and used to design primers for exon scanning.
PCRs for the cloning of PAX6 were run in a 25 µl reac-
tion volume with the following conditions: 2 min at 94 °C
followed by 30 cycles of 60 s at 94 °C, 60 s at 58 °C, 60 s at 72
°C, and a final extension of 7 min at 72 °C. PCRs were run on
Amplitron II® Thermolyne thermocyclers (Barnstead
Thermolyne Co., Dubuque, IA), and amplified products were
electrophoresed on 2% agarose gels (Invitrogen, Carlsbad, CA)
with 1X TAE buffer (0.04 M Tris-acetate buffer, pH 8, 100
mM EDTA) at 60V. Gels were stained with ethidium bromide,
visualized using an ultraviolet transilluminator (Spectronics
Corporation, Westbury, NY), and digitally photographed. PCR
products were purified using the Concert™ PCR purification
kit (Gibco, BRL, Gaithersburg, MD), or gel bands were ex-
cised and purified using the Qiaex II® Gel Extraction kit
(Qiagen Inc., Valencia, CA). Purified PCR products were then
sequenced on the Applied Biosystems Automated 3730 DNA
Analyzer using Big Dye Terminator chemistry and Ampli Taq-
FS DNA Polymerase. Sequence assembly and analysis were
performed using Sequencher™ software (Gene Codes Cor-
poration, Ann Arbor, MI).
Exon scanning:  PAX6 exons, along with their intron/exon
junctions, were scanned using PCR amplification of gDNA
from 4 aniridia-affected dogs (GD5, GD6, GD9, and GD10),
and 3 non-affected dogs (GD2, GD3, and GD8) from the same
pedigree. In addition, one non-affected unrelated Beagle (B15)
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Figure 1. The canine aniridia phenotype.  Note the absence of iris,
visible ciliary processes located near the lens equator (white arrow-
heads) and pupillary membrane remnants (black arrows).
432was scanned as a control. Primers were designed in introns
near the intron/exon boundaries (Table 2) using Amplify soft-
ware. Primers in nearby exons were used in the amplification
of exons 5a, 6, 9, 10, and 11. PCR and electrophoresis condi-
tions were the same as those described earlier. Gel bands cor-
responding to exon sizes were excised and gel purified using
the QIAquick® Gel Extraction kit (Qiagen Inc.). Gel-purified
PCR products were sequenced and analyzed as previously
described.
Radiation Hybrid Mapping:  Canine PAX6 was positioned
on a radiation hybrid map using a canine/hamster radiation
hybrid (RH3000) panel consisting of 92 cell lines made by
fusing 3000 rad-irradiated canine fibroblast cells with TK-
HTK3 hamster cells (Research Genetics, Inc., Huntsville, AL).
Canine PAX6 was linked to CFA18 in relation to 7 gene mark-
ers (WT1, CD44, COLF1, COLF2, DLA79, ROM1, and
TPCR63) and 7 microsatellite markers (Wilms-TF, REN47J11,
REN248C19, C18.156, C18.460, AHT130, and FH2356). All
of these markers were previously mapped and positioned on
CFA18 [21,22]. Primers for RH mapping are listed in Table 3.
PAX6 primers 30F and 21R, which amplify intron 8, were used
to amplify PAX6 in the RH3000 panel.
PCR reactions were run on the 92 cell lines of the RH3000
panel, in duplicate or triplicate, at 25 µl volume. PCR condi-
tions were as follows: 2 min at 94 °C, followed by 30 cycles
of 30 s at 94 °C, 30 s at 56 °C, 30 s at 72 °C, and a final
extension of 5 min at 72 °C. PCRs were optimized by adjust-
ing the annealing temperature as needed. PCR products were
electrophoresed and analyzed as described earlier. Gel images
were recorded for each gel and scored for presence or absence
of the band of interest in each of the 92 cell lines. Radiation
hybrid data was analyzed using Multimap® software [23].
Association Testing:  Ten dogs, 6 affected and 4 non-af-
fected, were used to test for association of aniridia with the
PAX6 locus. Seven of the ten animals were part of one small
pedigree and 3 were unrelated (Figure 3). Autosomal reces-
sive inheritance was assumed based on a previous report [18],
and limited pedigree information, but phenotypic variability,
prevented the exclusion of dominant inheritance with incom-
plete penetrance. In addition, a founder effect mutation was
hypothesized based on the small breed size. This mutation
appears to have occurred recently in that the previous clinical
[18] report is the first and only description of aniridia in the
breed, and, as this is a working dog breed, the visual impair-
ment caused by aniridia would be readily recognized in these
dogs once it occurred.
Four microsatellite markers (C18.156, COS18, Wilms-
TF, and REN47J11) which were previously mapped to CFA18
using an RH5000 panel [21,22] were used for association test-
ing along with 2 SNPs identified within canine PAX6: one in
exon 7 and one in intron 8. In exon 7 there is a T>C change
(ACT>ACC) at nucleotide 501 of the 1,311 bp coding sequence
(PAX6(5a)) that does not alter the translated amino acid (threo-
nine). In intron 8 (which is 484 bp), there is a G>A change at
intronic nucleotide position 351.
Primers used for association testing, along with PCR prod-
uct sizes, genomic locations, and inter-marker distances are
listed in Table 4. The previous RH5000 map placement of the
4 microsatellite markers gives 22.0 cRays between C18.156
and COS18, 57.5 cRays between COS18 and Wilms-TF, and
64.7 cRays between Wilms-TF and REN47J11 [22]. Accord-
ing to the current genomic sequence, PAX6 lies between Wilms-
TF and REN47J11 (Table 4). PCRs were run as previously
described, and products for microsatellite markers were elec-
trophoresed on 6% polyacrylamide gels, and microsatellite
sizes were scored for each animal. PCR products for the exon
7 SNP were electrophoresed on 2% agarose gels (Invitrogen),
gel purified, sequenced, and analyzed as previously described.
Intron 8 PCR products were digested with BstNI (New En-
gland Biolabs, Ipswich, MA) and electrophoresed on 6% poly-
acrylamide gels. Dogs homozygous (G/G) for the intron 8 SNP
had 230 bp and 220 bp bands, while heterozygous dogs (G/A)
had 230 bp, 220 bp, and 450 bp bands after enzyme digestion.
Homozygous (A/A) dogs would have a 450 bp band, but there
were none in this pedigree.
Southern blot:  Southern (DNA) analysis was performed
using 10 µg of gDNA from two non-affected dogs (GD2 and
GD8), two affected progeny (GD6 and GD10), and one con-
trol dog (beagle). Genomic DNA was digested with restric-
tion enzyme EcoR1 (New England Biolabs, Ipswich, MA),
electrophoresed on a 0.8% agarose gel, and transferred to a
nylon hybridization transfer membrane (GeneScreen Plus®
Perkin Elmer, Boston, MA). The nylon membrane was
prehybridized and hybridized with ExpressHyb™ (Clontech,
Palo Alto, CA). Probes were labeled with a P32dCTP (3,000
Ci/mmol, 10 mCi/ml) using the RadPrime DNA Labeling
System (Life Technologies™, Inc Palo Alto, CA).
Two probes were designed from the canine PAX6. A 580
bp fragment, including all of exon 1, intron 1, exon 2, and part
of intron 2, was used as a 5’UTR probe. This probe was am-
plified using primers PAX6-40F and 43R (Table 2). A 373 bp
fragment in the PST domain, including part of intron 11, all of
exon 12 and part of intron 12, was used as a 3' end probe. This
probe was amplified using PAX6-61F and 62R (Table 2). Each
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Figure 2. Spanish Catalan sheepdog pedigree showing aniridia-af-
fected dogs.  Note that the parents of affected dogs in 3 of the matings
were clinically normal.
433probe was amplified in gDNA, gel purified using the
QIAquick® Gel Extraction kit (QiagenIAGEN Inc.), and veri-
fied by sequencing.
RESULTS
Characterization of canine PAX6: A 1,072 bp fragment of
canine PAX6 cDNA, representing the 3' end of exon 4 through
the 5' end of exon 12, was amplified from a canine retinal
cDNA library using primers designed from human/mouse
PAX6 consensus sequence (Table 1). cDNA library vector prim-
ers, PBKIII and PBKVI, were used to extend the sequence to
1,472 bp which included the 3' end of exon 2 through the 5'
end of exon 13. This fragment contained the complete PAX6
coding sequence for isoform a, which does not contain the
alternatively transcribed exon 5a. This 1,269 bp coding se-
quence began at the ATG start codon in exon 4, and ended at
the TAA stop codon in exon 13. A poly-A sequence of at least
20 residues followed the stop codon, and it was unclear where
non-coding exon 13 ended. Similarly, in man the ATG start
codon occurs in exon 4, and the TAA stop codon in exon 13 is
followed by a poly-A sequence of 21 residues. Exon 13 in
man is estimated to be 1,110 bp (NM_001604). Unlike the
human and canine genes, mouse Pax6 contains 12 exons in-
stead of 13, and mouse exons 2-12 correspond with human
and canine exons 3-13 (Figure 4). As a result, the mouse ATG
start codon is in exon 3 (instead of exon 4), and the TAA stop
codon is in exon 12 (instead of exon 13), and it is not followed
by a poly-A sequence (NM_013627).
A 42 bp alternatively transcribed exon 5a was amplified
from the canine retinal cDNA library, and was located between
exons 5 and 6, as in man. This alternatively transcribed exon
is located between exons 4 and 5 in the mouse. The coding
sequence for canine PAX6 isoform b, which includes this al-
ternatively transcribed exon, was 1,311 bp, and was the same
length as the human and mouse PAX6(5a) coding sequences.
Sequences for exon 1 and the 5' end of exon 2 could not
be amplified from the cDNA library, and were obtained from
the TIGR 1.5X (poodle) canine genomic sequence [20]. Within
the 5' UTR, the predicted sizes for canine exons 1 and 2, and
introns 1 and 2, were similar in size to the corresponding hu-
man exons and introns (Table 5). Exon 1 was predicted to be
103 bp based on the TIGR canine genomic sequence, and se-
quences amplified from genomic DNA in canine patients. In
man, PAX6 exon 1 is 119 bp (NM_001604) or 196 bp
(NM_000280). PAX6 exon 2 is 188 bp in man (NM_001604
and NM_000280), and predicted to be 224 bp in the dog. The
additional 36 bp in canine exon 2 included a 23 bp poly-A
sequence near the center of the exon followed by highly re-
petitive sequence. In the mouse, the comparable exon 1 is 386
bp (NM_013627), while exon 2 is 80 bp and corresponds with
human and canine exon 3 (77 bp; Figure 4 and Table 5).
The canine PAX6 cDNA sequence (1,786 bp) represent-
ing exons 1-13, including exon 5a, and a 20 bp poly-A 3' end,
was analyzed against the 2005 canine 7.6X genomic sequence
(boxer) using the blat function. As of November, 2006, there
was 99.9% identity spanning >21 kb in the genomic sequence
(38,671,042-38,692,610) on chromosome 18. Matching se-
quences were identified for exons 3-4, and 9-13. However,
PAX6 exons 1-2 and 5-8 (including exon 5a) were missing
from the current canine draft sequence. A 714 bp gap in the
canine sequence, from 38,666,389-38,667,102, included pre-
dicted exons 1 and 2, while a second, larger 12,622 bp gap
from 38,675,042-38,687,663, included exons 5-8. As a result,
©2007 Molecular Vision Molecular Vision 2007; 13:431-42 <http://www.molvis.org/molvis/v13/a46/>
TABLE 1. PRIMER SEQUENCES USED TO CLONE PAX6 FROM A CANINE
RETINAL CDNA LIBRARY
                                                          Product
                                                    Tm     size
 Primer    Location            Sequence            (°C)    (bp)
--------   ---------   -------------------------   ----   -------
PAX6-1F    exons 4-5   GCAGAACAGTCACAGCGGAGTG      60.4     464
PAX6-3R    exon 7      CCGTCTGCGCCCATCTGTTG        61.4
PAX6-4F    exon 7      GTCATCAATAAACAGAGTTCTTCGC   54.3     485
PAX6-5R    exon 10     GTGTTGCTGGCCTGTCTTCTCTG     60.1
PAX6-6F    exon 9      GATCTACCTGAAGCAAGAATACAGG   54.9     380
PAX6-7R    exon 12     GGTGTAGGTATCATAACTCCG       51.9
   Primers used to clone 5' end of PAX6
PBKIII F   vector      GGTCGACACTAGTGGATCCAAAG     57.1     550
PAX6-3R    exon 7      CCGTCTGCGCCCATCTGTTG        61.4
   Primers used to clone 3' end of PAX6
PAX6-6F    exon 9      GATCTACCTGAAGCAAGAATACAGG   54.9     600
PBKVI R    vector      GCTCTCATGAAGATCTCGCCG       57.7
PAX6-27F   exon 12     AACAGTCAGCCAATGGGCAC        53.7     200
PBKVI R    vector      GCTCTCATGAAGATCTCGCCG       57.7
   Primers used to amplify alternatively transcribed EXON 5a
PAX6-14F   exon 5      CTCGGTGGTGTCTTTGTCAAC       54.2     250
PAX6-15R   exon 6      CTACTCTCGGTTTACTACCACC      54.7
TABLE 2. PAX6 PRIMER SEQUENCES USED FOR EXON SCANNING
                                                                Product
                                                          Tm     size
Exon    Primer (location)         Primer sequence        (°C)    (bp)
----   -------------------   -------------------------   ----   -------
1      PX6-40F (5’UTR)       TCAGGCGCAGGAGGAAGTG         59.9     194
       PX6-41R (intron 1)    TCAGCGGCTGGAGAGTGAG         59.3
2      PX6-42F (intron 1)    CTCACTCTCCAGCCGCTGAC        60.1     400
       PX6-43R (intron 2)    CTCTCCCGGCGTGGCAGTG         63.6
3      PX6-44F (intron 2)    GAGAGTCCATGGGCCTGTGC        60.6     200
       PX6-45R (intron 3)    CTTCTCCCATGTGAACAATGAAG     53.9
4      PX6-84F (intron 3)    GCGACTGAGTGGATCCCTTC        58.2     302
       PX6-83R (intron 4)    CCCTCCAGCCGGACTGC           61
5      PX6-86F (intron 4)    CCGCATGGACGTGTGGTCC         61.7     558
       PX6-79R (intron 5)    GGAGTTATCTTATGTGACTGAC      51.4
5A     PX6-50F (intron 5)    CTCTCTACAGTAAGTTCTCATAC     49.6     210
       PX6-39R (exon 6)      CCAGTCTCGTAATACCTGCC        53.7
6      PAX6-34F (exon 5A)    GTCCAAGTGCTGGACAATC         51       917
       PAX6-29R (intron 6)   AACAAGCTCCCAGCCATCCT        53.7
7      PX6-51F (intron 6)    GTTGTTCTTTAAGAGAGTGGGTG     53.5     310
       PX6-52R (intron 7)    CCAGTGGCTGCCTATATGGAG       57.3
8      PX6-53F (intron 7)    GCCTCTTTGGGAGGCTCCAAG       60.4     300
       PX6-54R (intron 8)    CTGGCTAAATATAGCTCTTTGTAC    51.2
9      PAX6-30F (intron 8)   GCCACATCTTCAGTACAAAG        49.6     800
       PX6-21R (exon 10)     GCCTGTCTTCTCTGGTTCC         53.1
10     PAX6-6F (exon 9)      GATCTACCTGAAGCAAGAATACAGG   54.9     590
       PX6-23R (exon 11)     GTGTTTGTGAGGGCTGTGTC        53.7
11     PX6-22F (exon 10)     CCCAGTCACATCCCCATCAG        55.8     350
       PX6-55R (intron 11)   CCCACTCCTCGCTTCTCCG         60.1
12     PX6-61F (intron 11)   CGATCATCAGGCTATCATAC        49.9     415
       PX6-62R (intron 12)   CCAGGAGGTTTCTCTTAAGG        52.2
13     PX6-63F (intron 12)   CATAGTCCATGCTTGTCTCTC       52.7     318
       PX6-88R (3’UTR)       CACAGGACACAACTGCAGAAC       57.4
434our cloned sequence provides the complete PAX6 coding se-
quence (accession numbers EF141016, and EF141017) which
was unavailable from the latest canine genomic sequence.
Primers designed to cross introns were used to determine
intronic sizes for 9 of the 13 canine introns. The estimated
sizes of the remaining 4 introns (2, 4, 7, and 11) were deter-
mined using genomic sequence information from TIGR 1.5X
(poodle) [20] and the 7.6X (boxer) [17] public canine genome
sequence (Figure 4). Canine exons 3-12, and intron 5a are
identical in size to the human counterparts, while exons 1,
and 2, and introns 1-12 are similar in size (Table 5). Both ca-
nine and human isoform b (PAX6[5a]) nucleotide coding se-
quences were 1,311 bp and shared 97.3% identity, while the
corresponding amino acid sequences shared 99.8% identity
(Figure 5). Interestingly, the canine and mouse coding se-
quences were only 93.2% identical, and had 89 nucleotide dif-
ferences: 15-PD, 13-Linker, 11-HD, 50-PST. Eighty-four of
the 89 nucleotide differences between dog and mouse occurred
in the 3rd codon position and represented silent changes. Of
the 5 nucleotide differences which occurred in the first codon
position, only two resulted in an amino acid change: PAX6(5a)
coding sequence nucleotide position 178 in exon 5a (PD) coded
for glutamine (CAA) in the dog and man, but glutamic acid
(GAA) in mouse; nucleotide position 1,213 in exon 12 (PST)
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TABLE 3. PRIMERS USED FOR RADIATION HYBRID MAPPING
435coded for alanine (GCC) in the dog and threonine (ACC) in
mouse and man.
Exon scanning:  The 14 exons of canine PAX6 were
scanned for mutations, including predicted exons 1 and 2,
cloned exons 3-13, and the alternatively transcribed exon 5a.
Splice sites at the intron/exon boundaries were also examined;
at least 27 intronic nucleotides before each exon, and at least
30 intronic nucleotides after each exon were included in the
analysis. PAX6 exon scans were performed in 7 dogs that were
part of one pedigree; this included 4 aniridia-affected dogs
and 3 non-affected related dogs (Figure 2). Non-coding exon
2 (224 bp) contained a 23 bp poly-A region followed by 6
AACC repeats. The first 133 bp of exon 2 was scanned in all
7 dogs, and the complete exon 2 sequence was scanned in 2
affected dogs (GD 5, 6) and 2 normal dogs (GD 3, 8). These 4
dogs had an extra AACC repeat in non-coding exon 2.
PAX6 exon scanning also revealed 2 single nucleotide
polymorphisms (SNPs). The first was located in exon 7 at
nucleotide position 501 (within the 1311 bp coding sequence),
and involved a C>T change at the third position of the codon
which did not alter the amino acid coded (ACC to ACT; threo-
nine). The second SNP occurred in intron 8 (484 bp) at intronic
nucleotide position 351, and was an A>G transition. Both of
these SNPs were silent changes which did not alter the trans-
lated amino acids. No pathological mutations were identified
in all 14 exons scanned or in their exon/intron junctions.
Radiation hybrid mapping:  A canine/hamster radiation
hybrid (RH3000) panel was used to link canine PAX6 to CFA
18 in relation to 7 gene markers and 7 microsatellite markers
(Table 3) which were mapped in previous studies [21,22].
Multimap® analysis could only place 8 of the 15 markers at
unique map positions. PAX6 and 6 other markers were placed
on CFA18, but could not be localized to a unique position in
relation to the other markers. However, two-point linkage
analysis linked canine PAX6 to Wilms-TF and WT1 on CFA18,
with LOD scores of 8.0 and 7.1, respectively. Wilms-TF and
WT1 are both located on CFA18 in a region with homology to
HSA11p13, [22,24,25] which is where human PAX6 is located.
Similar map locations between the canine and human PAX6
genes further supports their homology.
Association testing:  Having excluded disease-associated
changes in the coding sequence, we examined whether there
was an association of PAX6 with the disease locus. Ten Catalan
sheepdogs (6 affected and 4 non-affected) were tested for as-
sociation of PAX6 with the aniridia phenotype. Seven of these
dogs were related and part of the same pedigree, while 3 dogs
were unrelated (Figure 3). Because of the limited genetic stud-
ies to date, it was not definitive whether this disease was re-
cessive or dominant. Based on a prior report [18], and the
production of affected dogs from non-affected parents, reces-
sive inheritance was assumed. Furthermore, based on the small
breed size, we hypothesized also that all aniridia-affected dogs
resulted from a founder-effect mutation. Thus, if the disease
is autosomal recessive, all affected dogs would be homozy-
gous for a common haplotype segment of CFA18. Alterna-
tively, if the disease is autosomal dominant with incomplete
penetrance, all affected dogs would have at least one common
haplotype segment of CFA18.
Six polymorphic markers on CFA18 were analyzed that
included 4 microsatellite markers (C18.156, COS18, Wilms-
TF, and REN47J11), and 2 PAX6 SNPs (exon 7 and intron 8).
All 10 dogs examined shared at least one common haplotype
for all 6 markers (Figure 3; “111TG1”). Four of the 6 affected
dogs (GD6, GD9, GD10, and GD14) were homozygous for
this common haplotype, while 2 affected dogs (GD5 and
GD12) were heterozygous. All affected dogs, regardless of
homozygosity or heterozygosity for this haplotype, showed a
broadly similar aniridia phenotype. Haplotypes for GD5 and
GD12 were repeated to confirm their heterozygosity. All 4
unaffected dogs (GD2, GD3, GD8, and GD13) were heterozy-
gous for the common haplotype. At 4 of the 6 individual marker
loci (C18.156, COS18, WILMS-TF, and exon 7 SNP) both
normal and affected dogs shared common genotypes. For 2
marker loci (intron 8 SNP and REN47J11) non-affected dogs
had both homozygous and heterozygous genotypes while all
affected dogs were homozygous. Furthermore, at each marker
locus there were both affected and non-affected animals with
identical genotypes. Such degree of haplotype sharing is not
unexpected given the small breed size and degree of inbreed-
ing.
Assuming recessive inheritance, our observations sug-
gested no association of the PAX6 locus with the aniridia phe-
notype. However, if aniridia segregates as a dominant disease
in these dogs, our observations would suggest an association
in that all affected dogs shared at least one common haplotype
(“111TG1”). Incomplete penetrance could explain the pres-
ence of this commom haplotype in “non-affected” dogs (GD2,
GD3, GD8, and GD13) that did not manifest the aniridia phe-
notype.
Southern blot analysis:  A Southern blot analysis was per-
formed using probes designed from both the 5' UTR (exon 1,
intron 1, exon 2, and the 5' end of intron 2) and the 3' PST
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Figure 3. Test for association of aniridia phenotypes with CFA18
markers.  Four microsatellites and 2 single nucleotide polymorphisms
were analyzed in 10 dogs (6 affected, and 4 non-affected). Two of
the 6 affected dogs were heterozygous; one of these was hetrozygous
for the PAX6 exon 7 SNP.
436domain (3' end of intron 11, all of exon 12, and the 5' end of
intron 12) of PAX6. Identical bands were found in affected
and non-affected dogs from the aniridia pedigree, and a nor-
mal beagle control using both probes. The 5' UTR probe hy-
bridized at about 8,500 bp, while the 3' PST probe hybridized
at about 7,400 bp (data not shown). The absence of any dis-
tinction between the PAX6 bands of affected and non-affected
animals using both a 5' and a 3' end probe suggested that there
were no large deletions present in the PAX6 gene.
DISCUSSION
 Human aniridia (OMIM 106210) patients show varying de-
grees of iris loss including complete to partial absence of the
iris, iris coloboma, and thinning of the iris. They may also
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Figure 4. Comparison of canine, human and mouse PAX6 organization.  Open boxes represent non-coding exons, and closed boxes represent
coding exons. Exon sizes are given above exon boxes. Lines represent introns with sizes written above.
TABLE 4. PRIMER SEQUENCES USED FOR ASSOCIATION TESTING AND GENOMIC LOCATION OF AMPLICONS
                                                             Product                               Distance
                                                       Tm     size          Canine genomic         between
       Primer name              Primer sequence       (°C)    (bp)         sequence location       markers
-------------------------   -----------------------   ----   -------   -------------------------   --------
C18.156-F (AC)15            ACAACCAACACACACAAAAACC    54.7     136     Chr18:25401870+25402003
C18.156-R (AC)15            TGTTATCCCAGTGGCATTAGG     54.5                                          2.2 Mb
COS-18-F (TC)19             CGTGGTGCCGGCCCTTTGAT      63.4     360     Chr18:27577535-30076377*
COS-18-R (TC)19             TTTAGCGCCTGCCTTTGGAC      58.4                                          8.1 Mb
Wilms-TF-F (tetra repeat)   CCCAATCTCCAGAGATTTTCC     52.3     300     Chr18:38163822+38164112
Wilms-TF-R (tetra repeat)   CCAGTCTCAGCTGTGTCCAA      53.7                                          510 Kb
PAX6-51F (exon 7 SNP)       GTTGTTCTTTAAGAGAGTGGGTG   53.5     310     Chr18:38675041-38687464**
PAX6-52R (exon 7 SNP)       CCAGTGGCTGCCTATATGGAG     57.3                                          2.8 Kb
PAX6-30F (intron 8 SNP)     GCCACATCTTCAGTACAAAG      49.6     824     Chr18:38687699+38688522
PAX6-21R (intron 8 SNP)     GCCTGTCTTCTCTGGTTCC       53.1                                          6.6 Mb
REN47J11-F (CA)11           TCTCCTCGCGTGTTTCTG        50.2     163     Chr18:45329434-45329603
REN47J11-R (CA)11           GGGGACACTCAGAAGGACG       55.3
The exact location of COS18* and PAX6 exon 7** could not be determined in the current canine genome draft sequence. The site given for
COS18 represents the region between its flanking markers BAC_375-H17 and BAC_373-K16 [24,25]. The site given for exon 7 represents the
last sequence before a gap in the genome which occurs in intron 4, and the calculated location of the beginning of exon 8, which is also located
within the gap.
437exhibit other related ocular abnormalities including cataract,
keratitis, or glaucoma. In this study, the clinical manifestation
of aniridia in a canine model strongly resembled that seen in
human patients. Canine subjects showed total to nearly com-
plete absence of the iris with ciliary processes visible at the
circumferential border; in some cases, cataracts, corneal
edema, and glaucoma also were present. The anatomical simi-
larities between the dog and human eye, along with the clini-
cal similarities in canine and human aniridia phenotypes, make
the dog an important model for this disease.
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TABLE 5. COMPARISON OF HUMAN, CANINE AND MOUSE PAX6 EXON AND INTRON SIZES.
The asterisk indicates that human sizes were determined using reference sequence NM_001604 and the UCSC human genome sequence. The
double asterisk indicates that mouse sizes were determined using reference sequence NM_013627 and the UCSC mouse genome sequence.
The “cross” indicates that canine intron 2 and 7 estimates are based on the TIGR 1.5X (poodle) sequence. ∆Canine intron 4 and 11 estimates
are based on UCSC 7.5X (boxer) sequence. The complete size of canine exon 13 is unknown. The ATG start codon is located in human and
canine exon 4, and mouse exon 3. The TAA stop codon is located in human and canine exon 13, and mouse exon 12.
438©2007 Molecular Vision Molecular Vision 2007; 13:431-42 <http://www.molvis.org/molvis/v13/a46/>
Figure 5. Comparison of the canine and human
PAX6 coding sequence (CDS), and amino acid se-
quence.  Human (NM_001604) CDS (first row);
canine (EF141016) CDS (second row); correspond-
ing amino acid sequence (436 aa; third row). The
first underlined region is the paired domain (426
bp), followed by the linker region (234 bp). The
second underlined region is the homeodomain (183
bp), followed by the PST domain (459 bp). The as-
terisks mark the 36 nucleotide differences between
dog and man, two in the paired domain; three in the
linker; five in the homeodomain; and 26 in the PST
domain. Thirty-five of the 36 nucleotide differences
occurred in the third position of the triplet codon,
and did not alter the translated amino acid. Only
one nucleotide difference occurred at the first posi-
tion of a codon (base pair 1,213) resulting in an
ACC (threonine) in man, and a GCC (alanine) in
the dog. This change occurred in exon 12 which
was part of the PST domain. As a result, the human
and canine PAX6 nucleotide coding sequences were
97.3% identical, and the corresponding amino acid
sequences were 99.8% identical.
439Because the vast majority of aniridia cases in man are
caused by mutations in the PAX6 gene [26] we used the candi-
date gene approach to evaluate PAX6 in the study population.
PAX6 was cloned from a canine retinal cDNA library, and
linked to WT1 and Wilms-TF on CFA18 using an RH3000
panel. A previous study placed PAX6 on CFA18 in the same
region between markers FH3824 and CFOR04B04 using an
RH5000 panel [27]. WT1 is just 4 cRays away from marker
FH3824, and 14 cRays from CFOR04B04 on the RH5000,
4249-marker map [25]. Integrated canine maps demonstrate
homology between CFA18 and human chromosomes 7 and
11 [28-30]. PAX6 is located in a region of CFA18 which has
homology with human chromosome 11p13, where PAX6 is
located in man.
The canine PAX6 cDNA sequence was 1,786 bp, and in-
cluded predicted exons 1 and 2, and cloned exons 3-13, plus
alternatively transcribed exon 5a (EF141016, EF141017). This
cDNA has sequence identity with the current canine genomic
sequence over a span >21 kb in length (38,671,042-38,692,610)
[17]. This presumably represents the genomic length of the
canine PAX6 gene. The human PAX6 genomic sequence is
22.4kb (NM_001604), while the mouse genomic sequence is
20.6kb (NM_013627). Canine PAX6 exons 3-4 and 9-13
matched sequences in the current genomic sequence. How-
ever, exons 1-2 fell within a 714 bp gap, and exons 5-8 fell
within a second 12,622 bp gap in the sequence. The exons
that are missing in the current draft canine genomic sequence
are provided by our cloning studies. Thus, this study fills in
the gaps left by the draft canine genome sequence, and pro-
vides a complete canine PAX6 sequence.
At the nucleotide level, the canine PAX6(5a) coding se-
quence (1,311 bp) had a higher degree of homology to the
human (NM_001604; 97.3% identical) than to the mouse
(NM_013627; 93.2% identical) sequence. Most of the nucle-
otide variations occurred within the PST domain: 26 of the 36
nucleotide differences between dog and human, and 50 of 89
differences between dog and mouse. Nevertheless, most of
the nucleotide differences occurred in the third codon posi-
tion and were synonymous changes which did not result in
corresponding amino acid changes (Figure 5).
At the amino acid level, canine PAX6 is 99.8% and 99.5%
identical, respectively, to the human and murine sequences.
The one amino acid difference between canine and human
sequences occurred in the PST region at codon 405 (nucle-
otide position 1213, within the 1311 bp coding sequence) which
codes for alanine in the dog, and threonine in man. The mouse
also has threonine at codon 405, and, in addition, the mouse
has glutamic acid in the PD at codon 60 (nucleotide position
178, within the 1311 bp coding sequence) while the dog and
human have glutamine. The extremely high PAX6 nucleotide
and amino acid sequence identities between dog, man, and
mouse suggest a consistency in protein structure and func-
tion.
Both canine (EF141016, EF141017) and human
(NM_001604) PAX6 contained 13 exons plus an alternatively
transcribed exon 5a. Exons 3-12 and intron 5a were the same
sizes in both species while intronic sizes were similar. The
mouse (NM_013627) gene, however, only has 12 exons (plus
exon 4a) with mouse exons 2-12 corresponding to canine and
human exons 3-13. The mouse coding sequence (exons 3-12)
was the same size as the corresponding coding sequences in
dog and human (exons 4-13). Mouse exon 2, and introns 1-12
were also similar in size to canine and human, but mouse exon
1 was 386 bp compared with 103 bp (dog) and 119 bp (hu-
man). Mouse exon 1 is more similar in size to canine and hu-
man exons 1 and 2 combined, 327 (canine) and 307 (human),
and may explain why the mouse has one less exon than the
canine and human genes.
No pathological mutations were detected in the canine
PAX6 coding sequence, non-coding exons, or in the intron/
exon junctions of aniridia-affected dogs. This included cod-
ing exons 4-13, the alternatively transcribed exon 5a, and the
non-coding exons 1-3 in the 5' UTR. Because the dogs used in
this study were privately owned pets or working dogs, we were
unable to obtain tissue samples to examine PAX6 RNA prod-
ucts to detect splicing defects or other transcript variants. We
also were unable to examine PAX6 expression in normal and
affected animals to rule out mutations in a promoter or en-
hancer.
Limitations in access to a larger sample size of dogs, or
the ability to carry out prospective matings, prevented confir-
mation of the mode of inheritance of canine aniridia, and cre-
ated difficulties in interpreting the association test. If canine
aniridia is inherited as a recessive trait, the association test
suggests no association of the PAX6 locus with the aniridia
phenotype. However, if canine aniridia is a dominant disease,
there appears to be association of PAX6 with aniridia in that
all affected dogs share at least one common haplotype
(“111TG1”). Dominance with incomplete penetrance could
account for the presence of this common haplotype in the “non-
affected” dogs (GD2, GD3, GD8, and GD13). Nonetheless,
the broadly similar aniridia phenotype present in dogs homozy-
gous or heterozygous for the “111TG1” haplotype argues
against dominant inheritance. This emphasizes the need for
further analysis of animals to establish the mode of inherit-
ance, and to conduct a more complete association test and seg-
regation analysis.
Regardless of the mode of inheritance, the Southern blot
analysis showed no difference in normal from affected dogs
using both a 5' and a 3' end probe which ruled out a large
deletion in the PAX6 gene. In the case of a recessively inher-
ited deletion, normal and affected dogs would be distinguish-
able on Southern analysis because all affected dogs would be
homozygous and have either no PAX6 band (if the probe is in
the deletion), or a smaller PAX6 band (if the probe is not in the
deletion, and the deletion is greater than or equal to 50 bp). In
the case of dominant inheritance, a large deletion in the PAX6
gene may go undetected in a heterozygous-affected dog if the
probe lies within the deletion. However, because we used both
5' and 3' end probes, we should detect a 5' end deletion with
the 3' end probe and vise versa, unless the entire gene is de-
leted. We know that the entire gene is not deleted because of
the heterozygosity detected in exon 7 (GD3, GD8, GD12, and
GD13) and intron 8 (GD3 and GD8) SNPs. It is very unlikely
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440that a genomic deletion that spares the exon 7 and intron 8
regions would also be unrecognizable using probes at both
the 5' and 3' ends of the gene. As a result, we have excluded a
large deletion in PAX6 as a cause of aniridia in the Catalan
sheep dog.
ACKNOWLEDGEMENTS
 We would like to express our sincere thanks and appreciation
to Vicki Meyers-Wallen, Anna Kukekova, James Kijas, Orly
Goldstein, and Keith Watamura for their help, support and
interest in this work. We would also like to thank Vicky
Baldwin for laboratory assistance in cloning. Funding was
provided by the National Institutes of Health (F32-EY13677,
EY-06855, and EY-13132), Cornell University Graduate Re-
search Assistantship, The Morris Animal Foundation, and the
Van Sloan Fund for Canine Genetic Research.
REFERENCES
 1. Sale MM, Craig JE, Charlesworth JC, FitzGerald LM, Hanson
IM, Dickinson JL, Matthews SJ, Heyningen Vv V, Fingert JH,
Mackey DA. Broad phenotypic variability in a single pedigree
with a novel 1410delC mutation in the PST domain of the PAX6
gene. Hum Mutat 2002; 20:322.
2. Hodgson SV, Saunders KE. A probable case of the homozygous
condition of the aniridia gene. J Med Genet 1980; 17:478-80.
3. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL.
PAX6 gene dosage effect in a family with congenital cataracts,
aniridia, anophthalmia and central nervous system defects. Nat
Genet 1994; 7:463-71. Erratum in: Nat Genet 1994; 8:203.
4. Walther C, Gruss P. Pax-6, a murine paired box gene, is expressed
in the developing CNS. Development 1991; 113:1435-49.
5. Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T,
van Heyningen V, Hastie ND, Meijers-Heijboer H, Drechsler
M, Royer-Pokora B, Collins F, Swaroop A, Strong LC, and
Saunders GF. Positional cloning and characterization of a paired
box- and homeobox-containing gene from the aniridia region.
Cell 1991; 67:1059-74.
6. Ton CC, Miwa H, Saunders GF. Small eye (Sey): cloning and
characterization of the murine homolog of the human aniridia
gene. Genomics 1992; 13:251-6.
7. Gerard M, Abitbol M, Delezoide AL, Dufier JL, Mallet J, Vekemans
M. PAX-genes expression during human embryonic develop-
ment, a preliminary report. C R Acad Sci III 1995; 318:57-66.
8. Grindley JC, Davidson DR, Hill RE. The role of Pax-6 in eye and
nasal development. Development 1995; 121:1433-42.
9. Halder G, Callaerts P, Gehring WJ. Induction of ectopic eyes by
targeted expression of the eyeless gene in Drosophila. Science
1995; 267:1788-92.
10. Chow RL, Altmann CR, Lang RA, Hemmati-Brivanlou A. Pax6
induces ectopic eyes in a vertebrate. Development 1999;
126:4213-22.
11. Lindsley DL, Zimm GG. The genome of Drosophila melanogaster.
San Diego: Academic Press; 1992.
12. Hill RE, Favor J, Hogan BL, Ton CC, Saunders GF, Hanson IM,
Prosser J, Jordan T, Hastie ND, van Heyningen V. Mouse small
eye results from mutations in a paired-like homeobox-contain-
ing gene. Nature 1991; 354:522-5. Erratum in: Nature. 1992;
355:750.
13. Favor J, Peters H, Hermann T, Schmahl W, Chatterjee B,
Neuhauser-Klaus A, Sandulache R. Molecular characterization
of Pax6(2Neu) through Pax6(10Neu): an extension of the Pax6
allelic series and the identification of two possible hypomorph
alleles in the mouse Mus musculus. Genetics 2001; 159:1689-
700.
14. Epstein JA, Glaser T, Cai J, Jepeal L, Walton DS, Maas RL. Two
independent and interactive DNA-binding subdomains of the
Pax6 paired domain are regulated by alternative splicing. Genes
Dev 1994; 8:2022-34.
15. Azuma N, Yamaguchi Y, Handa H, Hayakawa M, Kanai A,
Yamada M. Missense mutation in the alternative splice region
of the PAX6 gene in eye anomalies. Am J Hum Genet 1999;
65:656-63.
16. Yamaguchi Y, Sawada J, Yamada M, Handa H, Azuma N. Auto-
regulation of Pax6 transcriptional activation by two distinct
DNA-binding subdomains of the paired domain. Genes Cells
1997; 2:255-61.
17. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe
DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ 3rd, Zody
MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA,
Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E,
Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A,
Cuff J, Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M,
Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim
L, Koepfli KP, Parker HG, Pollinger JP, Searle SM, Sutter NB,
Thomas R, Webber C, Baldwin J, Abebe A, Abouelleil A, Aftuck
L, Ait-Zahra M, Aldredge T, Allen N, An P, Anderson S, Antoine
C, Arachchi H, Aslam A, Ayotte L, Bachantsang P, Barry A,
Bayul T, Benamara M, Berlin A, Bessette D, Blitshteyn B, Bloom
T, Blye J, Boguslavskiy L, Bonnet C, Boukhgalter B, Brown A,
Cahill P, Calixte N, Camarata J, Cheshatsang Y, Chu J, Citroen
M, Collymore A, Cooke P, Dawoe T, Daza R, Decktor K, DeGray
S, Dhargay N, Dooley K, Dooley K, Dorje P, Dorjee K, Dorris
L, Duffey N, Dupes A, Egbiremolen O, Elong R, Falk J, Farina
A, Faro S, Ferguson D, Ferreira P, Fisher S, FitzGerald M, Foley
K, Foley C, Franke A, Friedrich D, Gage D, Garber M, Gearin
G, Giannoukos G, Goode T, Goyette A, Graham J, Grandbois
E, Gyaltsen K, Hafez N, Hagopian D, Hagos B, Hall J, Healy C,
Hegarty R, Honan T, Horn A, Houde N, Hughes L, Hunnicutt
L, Husby M, Jester B, Jones C, Kamat A, Kanga B, Kells C,
Khazanovich D, Kieu AC, Kisner P, Kumar M, Lance K, Landers
T, Lara M, Lee W, Leger JP, Lennon N, Leuper L, LeVine S,
Liu J, Liu X, Lokyitsang Y, Lokyitsang T, Lui A, Macdonald J,
Major J, Marabella R, Maru K, Matthews C, McDonough S,
Mehta T, Meldrim J, Melnikov A, Meneus L, Mihalev A, Mihova
T, Miller K, Mittelman R, Mlenga V, Mulrain L, Munson G,
Navidi A, Naylor J, Nguyen T, Nguyen N, Nguyen C, Nguyen
T, Nicol R, Norbu N, Norbu C, Novod N, Nyima T, Olandt P,
O’Neill B, O’Neill K, Osman S, Oyono L, Patti C, Perrin D,
Phunkhang P, Pierre F, Priest M, Rachupka A, Raghuraman S,
Rameau R, Ray V, Raymond C, Rege F, Rise C, Rogers J, Rogov
P, Sahalie J, Settipalli S, Sharpe T, Shea T, Sheehan M, Sherpa
N, Shi J, Shih D, Sloan J, Smith C, Sparrow T, Stalker J, Stange-
Thomann N, Stavropoulos S, Stone C, Stone S, Sykes S,
Tchuinga P, Tenzing P, Tesfaye S, Thoulutsang D, Thoulutsang
Y, Topham K, Topping I, Tsamla T, Vassiliev H, Venkataraman
V, Vo A, Wangchuk T, Wangdi T, Weiand M, Wilkinson J, Wil-
son A, Yadav S, Yang S, Yang X, Young G, Yu Q, Zainoun J,
Zembek L, Zimmer A, Lander ES. Genome sequence, compara-
tive analysis and haplotype structure of the domestic dog. Na-
ture 2005; 438:803-19.
18. Villagrasa M. Aplasia-hipoplasia de iris con carácter hereditario
en el gos d’atura. Clinica Veterinaria de Pequeños Animales
1996; 16(4):201-205.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a labora-
©2007 Molecular Vision Molecular Vision 2007; 13:431-42 <http://www.molvis.org/molvis/v13/a46/>
441tory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring
Harbor Press; 1989.
20. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch
DB, Delcher AL, Pop M, Wang W, Fraser CM, Venter JC. The
dog genome: survey sequencing and comparative analysis. Sci-
ence 2003; 301:1898-903.
21. Mellersh CS, Hitte C, Richman M, Vignaux F, Priat C, Jouquand
S, Werner P, Andre C, DeRose S, Patterson DF, Ostrander EA,
Galibert F. An integrated linkage-radiation hybrid map of the
canine genome. Mamm Genome 2000; 11:120-30.
22. Breen M, Jouquand S, Renier C, Mellersh CS, Hitte C, Holmes
NG, Cheron A, Suter N, Vignaux F, Bristow AE, Priat C, McCann
E, Andre C, Boundy S, Gitsham P, Thomas R, Bridge WL,
Spriggs HF, Ryder EJ, Curson A, Sampson J, Ostrander EA,
Binns MM, Galibert F. Chromosome-specific single-locus FISH
probes allow anchorage of an 1800-marker integrated radiation-
hybrid/linkage map of the domestic dog genome to all chromo-
somes. Genome Res 2001; 11:1784-95.
23. Matise TC, Perlin M, Chakravarti A. Automated construction of
genetic linkage maps using an expert system (MultiMap): a
human genome linkage map. Nat Genet 1994; 6:384-90. Erra-
tum in: Nat Genet 1994; 7:215.
24. Guyon R, Lorentzen TD, Hitte C, Kim L, Cadieu E, Parker HG,
Quignon P, Lowe JK, Renier C, Gelfenbeyn B, Vignaux F,
DeFrance HB, Gloux S, Mahairas GG, Andre C, Galibert F,
Ostrander EA. A 1-Mb resolution radiation hybrid map of the
canine genome. Proc Natl Acad Sci U S A 2003; 100:5296-301.
25. Breen M, Hitte C, Lorentzen TD, Thomas R, Cadieu E, Sabacan
L, Scott A, Evanno G, Parker HG, Kirkness EF, Hudson R,
Guyon R, Mahairas GG, Gelfenbeyn B, Fraser CM, Andre C,
Galibert F, Ostrander EA. An integrated 4249 marker FISH/RH
map of the canine genome. BMC Genomics 2004; 5:65.
26. Prosser J, van Heyningen V. PAX6 mutations reviewed. Hum
Mutat 1998; 11:93-108.
27. Hunter LS, Sidjanin DJ, Johnson JL, Zangerl B, Galibert F, Andre
C, Kirkness E, Talamas E, Acland GM, Aguirre GD. Radiation
hybrid mapping of cataract genes in the dog. Mol Vis 2006;
12:588-96.
28. Breen M, Thomas R, Binns MM, Carter NP, Langford CF. Re-
ciprocal chromosome painting reveals detailed regions of con-
served synteny between the karyotypes of the domestic dog
(Canis familiaris) and human. Genomics 1999; 61:145-55.
29. Yang F, O’Brien PC, Milne BS, Graphodatsky AS, Solanky N,
Trifonov V, Rens W, Sargan D, Ferguson-Smith MA. A com-
plete comparative chromosome map for the dog, red fox, and
human and its integration with canine genetic maps. Genomics
1999; 62:189-202.
30. Sargan DR, Yang F, Squire M, Milne BS, O’Brien PC, Ferguson-
Smith MA. Use of flow-sorted canine chromosomes in the as-
signment of canine linkage, radiation hybrid, and syntenic groups
to chromosomes: refinement and verification of the compara-
tive chromosome map for dog and human. Genomics 2000;
69:182-95.
©2007 Molecular Vision Molecular Vision 2007; 13:431-42 <http://www.molvis.org/molvis/v13/a46/>
442
The print version of this article was created on 26 Mar 2007. This reflects all typographical corrections and errata to the article through that
date. Details of any changes may be found in the online version of the article. α